A structured roadmap for pharmaceutical manufacturers moving from paper-based production to an ISA-95 compliant digital architecture. Covers brownfield assessment, system architecture, MES selection, validation strategy and go-live sequencing.
Inventory existing PLCs, SCADA systems, ERP interfaces and batch records against the ISA-95 level model. Identify gaps in data flow, audit trail coverage and electronic signature capability before writing URS.
Define the target ISA-95 architecture: equipment hierarchy (process cells, units), MES scope, historian integration, OPC-UA/B2MML data interfaces and GMP boundary documentation for QA sign-off.
Apply GAMP 5 Category 4 validation methodology: functional specification, configuration specification, IQ/OQ/PQ protocols, and User Acceptance Testing. Parallel batch operation is recommended before decommissioning paper records.
Use this ISA-95 Implementation Roadmap for Pharma page as a planning checkpoint before vendor selection, architecture review, validation scoping or implementation sequencing. The strongest next step is to compare the guidance with your current SOPs, system inventory, batch records, data flows and QA review routines so the discussion starts from evidence instead of assumptions.
For ISA-95 Implementation Roadmap for Pharma, prepare the records, owners, risks and decision criteria linked to phase 0: brownfield assessment, phase 1: architecture and urs, phase 2: validation and go-live. Useful evidence includes current process maps, interface lists, audit trail expectations, exception workflows, data retention rules and the business reason for changing the current operating model.
The first step is a brownfield assessment: mapping existing equipment, control systems, data historians and ERP interfaces against the ISA-95 level model (Levels 0–4). This assessment identifies which data flows already exist, where audit trail gaps occur, and what minimum connectivity investment is needed before MES selection.
An ISA-95 MES is typically a GAMP 5 Category 4 system (configurable commercial software). Validation requires a vendor assessment, configuration specification documenting all GxP-relevant configurations, IQ/OQ/PQ protocols that test regulated functions (electronic records, audit trails, e-signatures), and User Acceptance Testing. Supplier test documentation can be leveraged to reduce scripted testing burden under the CSA approach.
Yes — phased implementation is the recommended approach for Vietnamese manufacturers. A common sequence starts with a data historian pilot on one production line to establish the data infrastructure, then adds MES/EBR for 2 products, then expands to QMS integration and full batch digitization. Each phase can be validated independently, reducing risk and enabling production to continue during the rollout.